Evercore ISI Upgrades Editas Medicine (EDIT) to Outperform

Evercore ISI analyst Liisa Bayko upgraded Editas Medicine (NASDAQ: EDIT) from Underperform to Outperform with a price target of $60.00 (from $20.00).

For an analyst ratings summary and ratings history on Editas Medicine click here. For more ratings news on Editas Medicine click here.

Shares of Editas Medicine closed at $46.05 yesterday.

You May Also Be Interested In

• New Street Research Upgrades Micron Technology (MU) to Buy
• Ladenburg Thalmann Upgrades ONE Gas Inc. (OGS) to Buy
• Travel Food Services (TRAVELFO:IN) PT Raised to INR1,600 at ICICI Securities